Aurora Cannabis (NASDAQ:ACB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aurora Cannabis (NASDAQ:ACB) from a sell rating to a hold rating in a research report sent to investors on Sunday morning,Wall Street Zen reports.

Other equities research analysts have also issued reports about the company. Weiss Ratings upgraded Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Zacks Research raised Aurora Cannabis from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. Finally, BMO Capital Markets upgraded Aurora Cannabis to a “hold” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Aurora Cannabis Trading Up 0.3%

NASDAQ:ACB opened at $3.82 on Friday. The company’s 50 day moving average price is $3.32 and its 200-day moving average price is $3.33. Aurora Cannabis has a 52 week low of $2.56 and a 52 week high of $6.66. The company has a quick ratio of 2.80, a current ratio of 5.36 and a debt-to-equity ratio of 0.03. The stock has a market cap of $247.69 million, a price-to-earnings ratio of -2.71 and a beta of 0.63.

Aurora Cannabis (NASDAQ:ACB) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.17. The company had revenue of $47.62 million during the quarter, compared to the consensus estimate of $47.45 million. Aurora Cannabis had a positive return on equity of 4.37% and a negative net margin of 32.26%. On average, equities research analysts forecast that Aurora Cannabis will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Tidal Investments LLC grew its position in shares of Aurora Cannabis by 1.2% during the second quarter. Tidal Investments LLC now owns 1,264,494 shares of the company’s stock worth $3,528,000 after purchasing an additional 14,827 shares in the last quarter. Two Sigma Securities LLC bought a new stake in Aurora Cannabis during the 2nd quarter valued at approximately $36,000. State of Wyoming purchased a new position in Aurora Cannabis in the 2nd quarter worth approximately $56,000. Baader Bank Aktiengesellschaft lifted its holdings in Aurora Cannabis by 37.3% in the 1st quarter. Baader Bank Aktiengesellschaft now owns 33,060 shares of the company’s stock worth $108,000 after purchasing an additional 8,990 shares in the last quarter. Finally, Leonteq Securities AG boosted its stake in Aurora Cannabis by 24.7% in the 1st quarter. Leonteq Securities AG now owns 42,839 shares of the company’s stock worth $140,000 after purchasing an additional 8,472 shares during the period. Institutional investors own 47.63% of the company’s stock.

About Aurora Cannabis

Aurora Cannabis Inc is a Canadian cannabis company focused primarily on the production, distribution and sale of medical cannabis products. The company offers products such as dried cannabis flower, pre-rolls, oils, capsules and other cannabis formats through medical and adult-use channels, depending on the applicable market.

Aurora markets products under brands including Aurora, MedReleaf and CanniMed. Its business also includes cannabis cultivation, product development, processing and distribution, supported by cultivation and production facilities in Canada and international operations.

Founded in 2013 and headquartered in Edmonton, Alberta, Aurora serves customers in Canada and selected international markets, including parts of Europe and Australia.